Patent Law Weblog
recent posts
- Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (2026)
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
about
Month: November 2008
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Eurand, Inc. et al. v. Mylan Pharmaceuticals, Inc. et al.1:08-cv-00210; filed November 26, 2008 in the Northern District of West Virginia Eurand,…
-
December 1, 2008 – 19th Annual Conference on U.S. Patent and Trademark Office Law and Practice (PTO Day) (Intellectual Property Owners Association) – Washington, DC December 2, 2008 – Patent Interferences Rules & Practice (Intellectual Property Owners Association) – Washington, DC December 3, 2008 – Biotechnology, Chemical, and Pharmaceuticals (BCP) Customer Partnership Meeting (U.S. Patent…
-
The biotechnology, chemical, and pharmaceuticals (BCP) technology groups at the U.S. Patent and Trademark Office will hold their next quarterly customer partnership meeting on December 3, 2008. The schedule of topics for discussion include (all times Eastern): Morning Session • Greetings and Overvie (9:00 – 9:15 AM): John LeGuyader, George Elliot, and Remy Yucel, Directors,…
-
By Donald Zuhn — Last Friday, Medco Health Solutions, Inc. added its name to the list of companies seeking a follow-on biologics (FOB) regulatory pathway (see Reuters report). The endorsement was not entirely surprising given Medco's vested interest — the company, based in Franklin Lakes, NJ, is the nation's largest mail order pharmacy and…
-
By Kevin E. Noonan — Maybe Hal Wegner (at right) is surprised by the continuing shenanigans of the current Patent Office administration. Maybe he is genuinely offended by their many actions and appointments made with seemingly little or no heed of the legal requirements for holding positions of authority in the Office. Or maybe he…
-
By Jason Derry — King Pharmaceuticals, Inc. has announced that it will purchase Alpharma Inc. for about $1.6 billion in cash. King had been trying to convince Alpharma to accept an offer for the past couple of months (see "King Pharmaceuticals Extends Tender Offer to Acquire Alpharma"). Alpharma has two marketed pain killer products,…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Abbott Laboratories et al. v. Teva Pharmaceuticals USA, Inc. et al.1:08-cv-06659; filed November 20, 2008 in the Northern District of Illinois Infringement…
-
December 1, 2008 – 19th Annual Conference on U.S. Patent and Trademark Office Law and Practice (PTO Day) (Intellectual Property Owners Association) – Washington, DC December 2, 2008 – Patent Interferences Rules & Practice (Intellectual Property Owners Association) – Washington, DC December 3, 3008 – Parallel Patent Reexamination and Litigation 2008: The Latest Developments and…
-
By Donald Zuhn — Yesterday, the U.S. Patent and Trademark Office published a notice in the Federal Register (73 Fed. Reg. 70282) clarifying the new appeals rules scheduled to take effect on December 10, 2008. The Patent Office also posted a statement regarding the clarification on its website. As we reported last summer, the…
-
By Donald Zuhn — On Tuesday, Alex Brill (at right), a principal at Matrix Global Advisors, LLC and former chief economist to the House Ways and Means Committee, released a white paper which asserts that a follow-on biologics regulatory pathway providing a data exclusivity period of seven years would be "sufficient for maintaining strong incentives…
Patent Docs 